Literature DB >> 25391381

Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Fabio Di Domenico1, Gilda Pupo1, Cesare Mancuso2, Eugenio Barone1, Francesca Paolini3, Andrea Arena1, Carla Blarzino1, Frederick A Schmitt4, Elizabeth Head5, D Allan Butterfield6, Marzia Perluigi1.   

Abstract

Bach1, among the genes encoded on chromosome 21, is a transcription repressor, which binds to antioxidant response elements of DNA thus inhibiting the transcription of specific genes involved in the cell stress response including heme oxygenase-1 (HO-1). HO-1 and its partner, biliverdin reductase-A (BVR-A), are upregulated in response to oxidative stress in order to protect cells against further damage. Since oxidative stress is an early event in Down syndrome (DS) and might contribute to the development of multiple deleterious DS phenotypes, including Alzheimer's disease (AD) pathology, we investigated the status of the Bach1/HO-1/BVR-A axis in DS and its possible implications for the development of AD. In the present study, we showed increased total Bach1 protein levels in the brain of all DS cases coupled with reduced induction of brain HO-1. Furthermore, increased oxidative stress could, on one hand, overcome the inhibitory effects of Bach1 and, on the other hand, promote BVR-A impairment. Our data show that the development of AD in DS subjects is characterized by (i) increased Bach1 total and poly-ubiquitination; (ii) increased HO-1 protein levels; and (iii) increased nitration of BVR-A followed by reduced activity. To corroborate our findings, we analyzed Bach1, HO-1, and BVR-A status in the Ts65Dn mouse model at 3 (young) and 15 (old) months of age. The above data support the hypothesis that the dysregulation of HO-1/BVR-A system contributes to the early increase of oxidative stress in DS and provide potential mechanistic paths involved in the neurodegenerative process and AD development.

Entities:  

Keywords:  Bach1; biliverdin reductase; heme oxygenase; oxidative stress; trisomy 21

Mesh:

Substances:

Year:  2015        PMID: 25391381      PMCID: PMC4677575          DOI: 10.3233/JAD-141254

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  89 in total

1.  Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part I).

Authors:  M S Cheon; S H Kim; M-L Yaspo; F Blasi; Y Aoki; K Melen; G Lubec
Journal:  Amino Acids       Date:  2003       Impact factor: 3.520

Review 2.  The brain in Down syndrome (TRISOMY 21).

Authors:  Gert Lubec; Ephrem Engidawork
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

Review 3.  Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies.

Authors:  Rukhsana Sultana; D Allan Butterfield
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn.

Authors:  Laura G Reinholdt; Yueming Ding; Griffith J Gilbert; Griffith T Gilbert; Anne Czechanski; Jeffrey P Solzak; Randall J Roper; Mark T Johnson; Leah Rae Donahue; Cathleen Lutz; Muriel T Davisson
Journal:  Mamm Genome       Date:  2011-09-28       Impact factor: 2.957

Review 5.  Down's syndrome: a pathology involving the lack of balance of reactive oxygen species.

Authors:  J Kedziora; G Bartosz
Journal:  Free Radic Biol Med       Date:  1988       Impact factor: 7.376

6.  Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part III).

Authors:  M S Cheon; S H Kim; V Ovod; N Kopitar Jerala; J I Morgan; Y Hatefi; T Ijuin; T Takenawa; G Lubec
Journal:  Amino Acids       Date:  2003       Impact factor: 3.520

Review 7.  4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.

Authors:  Marzia Perluigi; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-15       Impact factor: 8.401

Review 8.  Beta-amyloid, oxidative stress and down syndrome.

Authors:  Ira T Lott; Elizabeth Head; Eric Doran; Jorge Busciglio
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

Review 9.  The heme oxygenase/biliverdin reductase pathway in drug research and development.

Authors:  C Mancuso; E Barone
Journal:  Curr Drug Metab       Date:  2009-07-14       Impact factor: 3.731

Review 10.  Bach1, a heme-dependent transcription factor, reveals presence of multiple heme binding sites with distinct coordination structure.

Authors:  Shusuke Hira; Takeshi Tomita; Toshitaka Matsui; Kazuhiko Igarashi; Masao Ikeda-Saito
Journal:  IUBMB Life       Date:  2007 Aug-Sep       Impact factor: 3.885

View more
  24 in total

Review 1.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 2.  Associations between atherosclerosis and neurological diseases, beyond ischemia-induced cerebral damage.

Authors:  Dannia Colín-Castelán; Silvio Zaina
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 3.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

4.  Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models.

Authors:  Chiara Lanzillotta; Antonella Tramutola; Shelby Meier; Frederick Schmitt; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico; Jose F Abisambra
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.

Authors:  Antonella Tramutola; Gilda Pupo; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Chiara Lanzillotta; Diede Brokeaart; Carla Blarzino; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

6.  [Differential expression profile of miRNAs in amniotic fluid exosomes from fetuses with Down syndrome].

Authors:  K Ding; L Yu; Z Huang; H Zheng; X Yang; T Tian; R Xie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-02-20

7.  Loss of DNA polymerase β induces cellular senescence.

Authors:  Aqila A Ahmed; Cristine Smoczer; Brianna Pace; David Patterson; Diane Cress Cabelof
Journal:  Environ Mol Mutagen       Date:  2018-07-03       Impact factor: 3.216

8.  The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.

Authors:  Ilaria Zuliani; Chiara Lanzillotta; Antonella Tramutola; Antonio Francioso; Sara Pagnotta; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Journal:  Neurotherapeutics       Date:  2020-11-30       Impact factor: 7.620

Review 9.  Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.

Authors:  D Allan Butterfield; Barry Halliwell
Journal:  Nat Rev Neurosci       Date:  2019-03       Impact factor: 38.755

Review 10.  Oxidative Stress in Down and Williams-Beuren Syndromes: An Overview.

Authors:  Marta Ferrari; Stefano Stagi
Journal:  Molecules       Date:  2021-05-24       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.